Respiratory Biofeedback Added to Strengthening Training in Patients With Chronic Kidney Disease
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorUniversidad de Granada
About this trial
The goal of this clinical trial is to learn whether diaphragmatic biofeedback added to respiratory muscle training improves clinical and functional outcomes in adults with chronic kidney disease. It will also evaluate the feasibility and acceptability of this intervention.
The main questions it aims to answer are:
Is diaphragmatic biofeedback added to respiratory muscle training acceptable and well tolerated in patients with chronic kidney disease? Does this intervention reduce respiratory symptoms and complications in this population? Does diaphragmatic biofeedback added to respiratory muscle training improve cardiorespiratory capacity and quality of life? Researchers will evaluate diaphragmatic biofeedback combined with respiratory muscle training and a placebo intervention based on conscious breathing to assess its effects.
Participants will:
* Perform the assigned intervention three times per day for 6 weeks * Follow a structured respiratory muscle training program with diaphragmatic biofeedback * Be monitored for symptoms, respiratory complications, and perceived quality of life throughout the study
Eligibility criteria
Qualifiers
Adults aged ≥18 years
Diagnosis of chronic kidney disease (CKD) at any stage
Clinically stable condition, with no acute medical events in the previous 4 weeks
Ability to understand and follow breathing and training instructions
Disqualifiers
Acute respiratory infection or unstable pulmonary disease
Severe cognitive impairment or neurological condition limiting cooperation
Unstable cardiovascular disease or contraindications to respiratory muscle training
Recent thoracic or abdominal surgery (<3 months)
Trial design
Treatments tested in this trial
- Diaphragmatic biofeedback combined with respiratory muscle training
- PLACEBO INTERVENTION
Treatment groups
24 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov